Open label, single arm, single centre study to evaluate the safety/tolerability, immunogenicity and preliminary efficacy of AMV002 when co-administered with anti-PD-L1 immunotherapy, Durvalumab (MEDI4736), in patients with recurrent and/or metastatic HPV-related, p16 positive oropharyngeal squamous cell carcinoma (OPSCC)
Latest Information Update: 15 Nov 2021
At a glance
- Drugs AMV-002 (Primary) ; Durvalumab (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms DURVAX
Most Recent Events
- 01 Nov 2021 Planned End Date changed from 31 Mar 2022 to 15 Aug 2022.
- 01 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2021 Status changed from not yet recruiting to recruiting.